Cardiovascular revascularization medicine : including molecular interventions
-
Cardiovasc Revasc Med · Mar 2018
Clinical outcomes of coronary occlusion following transcatheter aortic valve replacement: A systematic review.
Coronary occlusion (CO) is a rare but serious complication following transcatheter aortic valve replacement (TAVR) with limited published data. We sought to evaluate the immediate and short-term outcomes of CO complicating TAVR. ⋯ CO following TAVR is associated with a high procedural and 30-day mortality rate despite aggressive resuscitative measures including percutaneous coronary intervention.
-
Cardiovasc Revasc Med · Sep 2017
Review Meta AnalysisBivalirudin versus heparin in women undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials.
The anticoagulant of choice during percutaneous coronary intervention (PCI) in women is not well established. ⋯ In women undergoing PCI, bivalirudin is associated with reduced risk of major bleeding and NACE compared with heparin especially when GPI is routinely used.
-
Cardiovasc Revasc Med · Sep 2017
Review Meta AnalysisBivalirudin versus heparin in women undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials.
The anticoagulant of choice during percutaneous coronary intervention (PCI) in women is not well established. ⋯ In women undergoing PCI, bivalirudin is associated with reduced risk of major bleeding and NACE compared with heparin especially when GPI is routinely used.
-
Cardiovasc Revasc Med · Jul 2017
ReviewTranscatheter versus surgical aortic valve replacement in patients with non-high surgical risk severe aortic stenosis: A systematic review.
Transcatether aortic valve replacement (TAVR) has emerged as an acceptable alternative to surgical aortic valve replacement (SAVR) in patients with high-risk surgical profile. In this analysis, we compare both approaches in non-high surgical risk severe aortic stenosis. ⋯ In severe AS patients with non-high surgical risk, TAVR has lower risk of MI at one month, but both TAVR and SAVR yielded similar outcomes at one month in terms of mortality and CVA and at 12months in terms of mortality, CVA and MI. In regard to secondary outcomes at one month, TAVR has lower rates of bleeding and acute kidney injury, and higher rates of need for new permanent pacemakers and high rate of vascular access site complications.